Navigation Links
Hologic, Inc. Announces Grant of Early Termination of Antitrust Waiting Period for Third Wave Technologies, Inc. Tender Offer
Date:6/25/2008

BEDFORD, Mass., June 25 /PRNewswire-FirstCall/ -- Hologic, Inc. (Nasdaq: HOLX) today announced that the Federal Trade Commission granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the "HSR Act"), on June 24, 2008, in connection with Hologic's previously announced tender offer for all of the outstanding shares of the common stock of Third Wave Technologies, Inc. (Nasdaq: TWTI). The early termination of the waiting period under the HSR Act satisfies the conditions to the tender offer related to the expiration or termination of any applicable waiting periods under the HSR Act and other state and foreign regulatory laws relating to the restraint of trade or lessening of competition. The tender offer remains subject to certain other conditions described in the Offer to Purchase.

As previously announced, Hologic commenced a Tender Offer on June 18, 2008 for all of the outstanding shares of Third Wave common stock for $11.25 per share in cash. The tender offer is scheduled to expire at 12:00 midnight, New York City time, on July 16, 2008.

About Hologic, Inc.

Hologic, Inc. is a leading developer, manufacturer and supplier of premium diagnostics, medical imaging systems and surgical products dedicated to serving the healthcare needs of women. Hologic's core business units are focused on breast health, diagnostics, GYN surgical, and skeletal health. Hologic provides a comprehensive suite of technologies with products for mammography and breast biopsy, radiation treatment for early-stage breast cancer, cervical cancer screening, treatment for menorrhagia, osteoporosis assessment, preterm birth risk assessment, and mini C-arm for extremity imaging. For more information visit http://www.hologic.com.

Additional Information

This description contained herein is neither an offer to purchase nor a solicitation of an offer to sell shares of Third Wave. The tender offer is being made pursuant to a Tender Offer Statement and related materials. Third Wave shareholders are advised to read the Tender Offer Statement and related materials filed by Hologic with the U.S. Securities and Exchange Commission (the "SEC"). At the time the tender offer commenced, Hologic and Thunder Tech Corp. (a wholly- owned subsidiary of Hologic) filed a Tender Offer Statement on Schedule TO containing an Offer to Purchase, the form of the letter of transmittal and other documents relating to the tender offer, and Third Wave filed a Solicitation/Recommendation Statement on Schedule 14D-9 with respect to the tender offer. These documents contain important information about the tender offer, including the terms and conditions of the tender offer, and shareholders of Third Wave are urged to read them carefully. Shareholders of Third Wave are able to obtain a free copy of these documents at http://www.hologic.com and the website maintained by the SEC at http://www.sec.gov. In addition, shareholders are able to obtain a free copy of these documents by contacting Hologic or Third Wave.

Contact:

Glenn P. Muir

Executive Vice President & CFO

Hologic, Inc.

(781) 999-7300

Frances Doria

Director, Investor Relations

Hologic, Inc.

(781) 999-7377


'/>"/>
SOURCE Hologic, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Hologic, Inc. to Host Investor Reception at the RSNA Trade Show
2. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
3. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
4. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
5. HEI, Inc. Announces Sale of RFID Division Assets
6. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
7. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
8. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
9. Brooke Franchise Corporation Announces Selected July Results
10. Manor Care, Inc. Announces Record Date for Special Stockholder Meeting
11. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/16/2017)... ... August 16, 2017 , ... For the ... New England student to educate the public on the impact of concussions. Brooke ... the first-ever National Concussion Awareness Day. , Brooke is working diligently is to ...
(Date:8/16/2017)... ... 16, 2017 , ... QualDerm Partners , a company ... announced Cumberland Skin Surgery and Dermatology has joined the company as ... both Hermitage and Lebanon, Tennessee, provides comprehensive general dermatology and skin cancer care ...
(Date:8/16/2017)... ... August 16, 2017 , ... ... received a three-year grant totaling $975,000, renewing its funding from the Health Resources ... Services. , This funding marks, the fourth time the HRSA administration has renewed ...
(Date:8/16/2017)... New Cumberland, PA (PRWEB) , ... August 16, 2017 , ... ... announced today it has successfully opened clubfoot clinics in all 29 Indian states—bringing the ... its newest clinic in Kangra, Himachal Pradesh, the nonprofit organization is on track to ...
(Date:8/16/2017)... ... 16, 2017 , ... Melbourne’s reign as the world’s most liveable city has ... annual Liveability Index. , The Index surveys 140 of the world’s cities and Melbourne ... has consistently come in the top three of the index. So what is it ...
Breaking Medicine News(10 mins):
(Date:8/3/2017)... , Aug. 3, 2017  Opioid addiction and ... driving up healthcare costs and threatening outcomes, were problems ... supply and IVD industry that support them, met this ... market researcher said that drugs of abuse, procalcitonin and ... sessions at the organization,s 69th meeting in ...
(Date:8/1/2017)... CerSci Therapeutics , a non-opioid drug development firm based ... notice from the National Institute on Drug Abuse (NIDA) ... has been awarded a Direct-to-Phase II Small Business Innovation ... an additional $1,000,000 to follow in 2018. These funds ... lead non-opioid drug candidate CT-044 to the Food and ...
(Date:7/28/2017)... July 28, 2017 EnvoyHealth, a Diplomat company, has ... program for CleverCap LITE, a technology designed to improve ... deliver innovative health technology solutions and services that help ... CleverCap LITE offers medication monitoring and ... cover: Records date ...
Breaking Medicine Technology: